Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion type Assertion NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_head.
- NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion wasGeneratedBy ECO_0000203 NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_provenance.
- NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion wasDerivedFrom befree-2016 NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_provenance.
- NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion SIO_000772 22271575 NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_provenance.
- NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion evidence source_evidence_literature NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_provenance.
- NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_provenance.